Cara Therapeutics, Inc. (CARA)

0,7922 +0,0022 (+0,28%) Al cierre: 04:00PM EDT

Cara Therapeutics, Inc.

400 Atlantic Street
Suite 500
Stamford, CT 06901
United States
203 406 3700
https://www.caratherapeutics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 55

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Christopher A. Posner	President, CEO & Director	1,15M	N/A	1970
Mr. Ryan D. Maynard	Chief Financial Officer	670,7k	N/A	1969
Dr. Derek T. Chalmers D.Sc., Ph.D.	Co-Founder & Senior Advisor	580,93k	N/A	1964
Dr. Iris Francesconi Ph.D.	Chief Strategy Officer & Head of Investor Relations	N/A	N/A	N/A
Mr. Scott M. Terrillion	Chief Compliance Officer, General Counsel & Corporate Secretary	689,63k	N/A	1963
Ms. Beth Weinberg R.Ph.	Senior Vice President of Regulatory Affairs & QA	N/A	N/A	N/A
Mr. Matthew Murphy	Manager of Investor Relations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Gobierno corporativo

El ISS Governance QualityScore de Cara Therapeutics, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 5; Tablero: 5; Derechos de los accionistas: 7; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.